Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 18.00
High: 18.00
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Slimbiome in Nutri-bites

8 Mar 2018 07:00

RNS Number : 9874G
OptiBiotix Health PLC
08 March 2018
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 Launch of Slimbiome® in Nutri-bites®

 

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, announces the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients ("CII"), at the 2018 Natural Products Expo West & Engredea. The exhibition is the world's largest trade show for organic, natural and healthy products and typically attract more than 80,000 food and ingredient buyers from around the world. OptiBiotix will join CII at stand 3788.

 

OptiBiotix has partnered with specialty ingredients manufacturer CII Ingredients, to launch its patented weight management technology, SlimBiome® in CII's Nutri-Bites® range of cereal based food products. This extends SlimBiome® applications from snack bars and shakes to breakfast cereals and bakery products (e.g. cookies, cakes and tortillas) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars.

 

Products in the Nutri-Bites® range contain expanded cereal pieces and are formulated with a choice of protein sizes and content. These can be applied to granola and snack mix inclusions, nutritional and cereal bars and coated snacks, or just used as a healthy crunch topping.

 

This is a continuation of OptiBiotix's focus on the US market following last years supply & manufacturing Aareement with CII, announced on 12 December 2017. SlimBiome® is the first in a range of products which helps to improve human health through the science of the microbiome. Other products under development in the range include ImmunoBiome, ® CardioBiome® and WellBiome®.

 

Cereal Ingredients is a privately held speciality ingredients manufacturer based in Kansas, USA, dedicated to the development, manufacture and supply of unique, high-quality food ingredients which contribute a meaningful point of difference.

 

Christina Wood, OptiBiotix Sales and Marketing Director, said: "Many cereals and snack bars on the market are deceptively high in sugar and calories, leading consumers with healthy intentions who use these products to gain, rather than lose, weight. By combining OptiBiotix's award winning SlimBiome® technology with CII's market-leading ingredients manufacturing capacity and product development, we have created a delicious functional solution which can help customers manage their weight by reducing snacking and food intake without food cravings. We are delighted to share this innovative science based approach to weight management with food and ingredient buyers from around the world at the Natural Products Expo West & Engredea show."

 

For more information about Optibiotix, please visit www.optibiotix.com

 

 

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUBSARWSAORAR
Date   Source Headline
14th May 20197:00 amRNSDistribution Agreement for SlimBiome® in Thailand
7th May 20197:00 amRNSLicense agreement for LPLDL®
2nd May 20197:00 amRNSInvestor evening
1st May 20197:00 amRNSSlimBiome launch to EU market at Vitafoods Europe
29th Apr 20197:00 amRNSFinal Results
24th Apr 20197:00 amRNSSlimBiome® Medical launches in UK market
11th Apr 20197:00 amRNSSlimBiome® receives approval from FSSAI in India
9th Apr 20197:00 amRNSSlimBiome® Medical agreement for Bulgaria
27th Mar 20193:18 pmRNSGrant of Options
27th Mar 20197:43 amRNSSweetBiotix®: Scientific and commercial update
27th Mar 20197:00 amRNSSweetBiotix®: Scientific and commercial update
25th Mar 201911:00 amRNSPrice Monitoring Extension
20th Mar 20197:00 amRNSExclusive distribution agreement for SlimBiome®
15th Mar 20197:00 amRNSExtension of term and territories for LPLDL®
13th Mar 20193:42 pmRNSExercise of Warrants
21st Feb 20197:00 amRNSLPLDL® determined GRAS by an Expert Panel in US
20th Feb 20197:00 amRNSPresentations at ProBiota - 2019
13th Feb 20197:00 amRNSTrading Statement
11th Feb 20197:00 amRNSDistribution agreement for LPLDL® in Japan
7th Feb 20197:00 amRNSSupply agreement for LPLDL® in the Baltic States
18th Jan 20191:56 pmRNSExercise of Warrants
11th Jan 20197:00 amRNSDirector Appointment
9th Jan 20197:00 amRNSDistribution agreement for CholBiome
7th Jan 20197:00 amRNSManufacturing agreement for SlimBiome®
17th Dec 20187:00 amRNSDirectorate Change
14th Dec 20187:00 amRNSIssue of Convertible Loan Notes by ProBiotix
5th Dec 20182:58 pmRNSHolding(s) in Company
4th Dec 20187:00 amRNSSlImBiome® Medical agreement for Greece and Cyprus
29th Nov 20187:00 amRNSSlimBiome Medical manufacturing agreement
27th Nov 20187:00 amRNSSlimBiome® granted medical device status & CE mark
22nd Nov 20187:00 amRNSCholBiome® agreement for Greece and Cyprus
11th Oct 20187:00 amRNSDirector's Dealing
9th Oct 20187:00 amRNSLPLDL® US manufacturing and supply agreement
8th Oct 20187:00 amRNSExercise of Options & Director's Dealing
3rd Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
1st Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
26th Sep 20187:00 amRNSDistribution agreement for CholBiome®
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 20187:00 amRNSFormation of ProBiotix Health Limited
10th Sep 20187:00 amRNSDirector Appointment
10th Sep 20187:00 amRNSLicence agreement with Bened Biomedical
10th Sep 20187:00 amRNSExercise of Warrants and Issue of Equity
4th Sep 20187:00 amRNSOptiBiotix signs US pharmaceutical deal
30th Aug 20187:00 amRNSHalf-year Report
6th Aug 20187:00 amRNSProposed directorate change
31st Jul 201810:04 amRNSDirector's dealing
17th Jul 20187:00 amRNSGrant of Options
12th Jul 20187:00 amRNSDirector's dealing
6th Jul 201812:00 pmRNSHolding(s) in Company
4th Jul 20182:07 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.